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Objectives: There is an increasing interest in cannabinoid-based products for the
treatment of refractory pediatric epilepsy. However, a licensed cannabidiol (CBD) product
was first approved for use by the European regulatory authorities in 2019. We aimed to
obtain knowledge about clinical experience and attitudes toward cannabinoid use for
epilepsy treatment among neuropediatricians in Scandinavia and Germany in the era
before a CBD-product was commercially licensed and available.
Study design: An internet-based questionnaire (Survey Monkey) was distributed by
email to members of neuropediatric societies in Sweden, Germany, Denmark, and
Norway between February and April 2018. One reminder email was sent.
Results: Eighty-six responded. Only 10 of 86 (12%) respondents had personal
experience with off-label prescription of cannabinoid-based products, mainly for severe
refractory pediatric epilepsies like Dravet syndrome and Lennox-Gastaut syndrome.
However, 49 respondents (57%) had been exposed to relatives of patients that had
requested or wanted to discuss cannabinoid therapy, and 32 (37%) respondents
knew about cannabinoid self-medication. The knowledge regarding cannabinoid-based
therapy among the respondents was overall limited. Main reasons for not prescribing
cannabinoid-based therapy were concerns about law regulations and lack of an
available product.
Conclusion: Off-label cannabinoid-based therapy for pediatric epilepsy was not widely
prescribed by neuropediatricians in Scandinavia and Germany in 2018.
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INTRODUCTION
Over the last decade there has been an increasing interest in cannabinoid-based products for
the treatment of refractory pediatric epilepsy (1). In animal studies cannabidiol (CBD) shows an
anticonvulsant profile largely devoid of the adverse psychoactive effects which is mainly related
to the tetrahydrocannabinol compound of cannabinoids (1). Anti-seizure properties of CBD are
Klingenberg et al. A Survey on Cannabinoid Treatment of Pediatric Epilepsy
probably mediated by modulation of intracellular calcium levels,
through inhibition of the G-protein coupled receptor GPR55
and activation of the transient receptor channel TRPV1, and
the inhibition of adenosine re-uptake (2). Until a few years ago
most data on the use of CBD-enriched extracts to treat pediatric
epilepsy had been based on observational studies, mainly from
the USA.
Since 2016, three randomized placebo-controlled adjunctive-
therapy trials of purified CBD-products including children and
adolescents with refractory epilepsy have been published (3–
5). In these trials, CBD was superior to placebo in reducing
the frequency of convulsive seizures in patients with Dravet
syndrome (3), and in reducing the frequency of drop-seizures in
patients with Lennox-Gastaut syndrome (LGS) (4, 5).
The objective of this survey was to obtain knowledge about
clinical experience and attitudes toward cannabinoid use for
epilepsy treatment among neuropediatricians in Scandinavia and
Germany in the era before a licensed product was available.
MATERIALS AND METHODS
Between February and April 2018 we distributed via email
an internet-based survey (Survey Monkey, Portland, OR,
USA) to members of neuropediatric societies in Sweden,
Denmark, and Norway. We assume that around 250–300
active neuropediatricians work in Scandinavia, but the sub-
specialization is not uniformly formalized and the number of
members of the neuropediatric societies is therefore uncertain
and may not reflect all neuropediatricians treating children with
epilepsy. We also sent the survey to a random group of 140
neuropediatricians in Germany. Email addresses were obtained
from society web sites or email lists, and distributed by designated
persons (see acknowledgment section).
The survey consisted of 16 questions using a combination
of open and fixed-response questions (Appendix in
Supplementary Material). We asked specific questions around
knowledge, experience and attitude regarding cannabinoid use
for pediatric epilepsy. Moreover, we asked whether parents or
relatives had asked for these treatments for their child, and to
what extent they knew about self-medication with cannabinoids.
Follow-up for non-responders was by one-1 reminder email.
Data are presented as number and percentages.
RESULTS
Eighty-six neuropediatricians responded; 42 (49%) were females
(Table 1). Fifty-six respondents (65%) had more than 10 years of
clinical experience in neuropediatrics, and 57 (66%) answered
that they treat children with epilepsy at least every week.
Eighty-one respondents (94%) had heard about of the use of
cannabinoids for treating epilepsy in children. Forty-seven (55%)
knew that CBD, and not THC, is the compound of cannabinoids
that is suggested to be most important for anti-epileptic activity.
Only 10 respondents (12%) had personally prescribed off-
label cannabinoids for treatment of children with epilepsy. These
caregivers had mostly prescribed a CBD oil or another purified
TABLE 1 | Response from 86 neuropaediatricians from Sweden (n = 26),
Denmark (n = 17), Norway (n = 23), and Germany (n = 20) on aspects related to
cannabinoid therapy for epilepsy.
Respondents who had prescribed cannabinoid-therapy (n = 10)
Indications x N (%)
• Lennox-Gastaut syndrome 5 (50)
• Dravet syndrome 4 (40)
• Infantile spasms 2 (20)
• Tuberous sclerosis 2 (20)
Perceived efficacy x
• Good seizure burden reduction (> 90%) 0 (0)
• Moderate seizure burden reduction (> 50%) 4 (40)
• Shortening of seizures 1 (6)
• Less “severe seizures” 4 (40)
• Better life quality 4 (40)
• Improved cognition 2 (20)
• No obvious effects 4 (40)
Respondents who had not prescribed cannabinoid-therapy (n = 76)
Reasons for not prescribing x
• No licensed product available 25 (33)
• National law regulations prohibits prescription 14 (18)
• Skepticism toward efficacy 21 (28)
• Lack of knowledge/experience 39 (51)
• Other 22 (29)
xMultiple answers possible.
CBD-formulation. The indications for using cannabinoids
and the perceived efficacy are shown in Table 1. We also
asked for adverse effects when cannabinoids were prescribed.
Lethargy/drowsiness, gastrointestinal symptoms, and decreased
appetite where those most frequently reported. We did not ask
for liver function abnormalities and none of the respondents
spontaneously reported this side effect.
The 76 respondents who had not prescribed cannabinoids for
pediatric epilepsy gave several reasons for not using this therapy
(Table 1). However, 49/76 (64%) had been exposed to parents
or relatives of patients that had requested or wanted to discuss
cannabinoid therapy. Moreover, 32 of all 86 respondents (37%)
were aware of cannabinoid self-medication, not prescribed by
a doctor.
DISCUSSION
This is the first survey on clinical experience and attitudes
toward use of cannabinoid therapy for refractory epilepsy among
neuropediatricians in North-Europe. A recent, similar online
survey reported data from 155 physicians treating children
or adolescents for epilepsy within eight countries in Central-
and South-Europe (7). In that survey 45% of the respondents
prescribed off-label cannabinoids (mainly CBD) for epilepsy, but
the response rate was not presented (5). Moreover, the authors
reported that individual experience with cannabinoid therapy
among responders was limited, and there were diverse opinions
about the use of CBD and how to manage the CBD treatment (7).
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The main finding of the current survey was that very few
neuropediatricians in Scandinavia and Germany had prescribed
off-label cannabinoid therapy for pediatric epilepsy. However,
those who had prescribed this therapy followed the indications
used in recent clinical trials on CBD-based therapy for refractory
epilepsies (3–5).
Respondents that had not prescribed cannabinoid-based
therapy gave different reasons. Concerns about law regulations
and lack of an available product (off-label use) was commonly
cited. This may change since a purified CBD-formulation
(Epidiolex R©/Epidyolex R©, GW Pharma) is approved by both the
American Food and Drug Administration (June 2018) and the
European Medicine Agency (September 2019). Recent clinical
trials support a possible adjunctive role of CBD-based therapy
for selected refractory epilepsies such as Dravet syndrome and
LGS, two of the most severe and difficult-to-treat forms of
childhood onset epilepsy (3–5). Long-term CBD treatment has
showed an acceptable safety profile and a sustained reductions
in seizure frequency in patients with these two epileptic
encephalopathies (2, 8–10). This was confirmed in two recently
published systematic reviews on CBD therapy including nearly
800 patients (children and adults) with Dravet syndrome (2) and
LGS (9). These systematic reviews concluded that adjunctive add-
on CBD therapy resulted in a significant reduction in seizure
frequency compared to placebo, but also in a higher rate of
adverse events (AEs). Typical AEs were somnolence, sedation,
decreased appetite, pneumonia, diarrhea, and increased liver
enzymes. Nevertheless, the overall conclusion was that add-
on CBD is an efficacious long-term treatment option for these
group of patients and that CBD is well-tolerated. CBD has
relatively few side effects, but interactions with other medications
should be monitored carefully (2, 9, 10). It also has to be
acknowledged that only a purified, pharmaceutical formulation
of cannabidiol has been authorized, and data from RCTs included
in these systematic reviews cannot be extrapolated to other
cannabinoid products.
The lack of clinical experience, but also theoretical knowledge,
with CBD therapy for epilepsy in children was striking in our
survey. In other countries, and in particular in the USA, off-
label use of cannabinoids has increased over the last decade
(1). Before initiating CBD-therapy clinicians must be aware of
the most common side effects such as gastrointestinal problems,
drowsiness, and liver function abnormalities (1, 3–5, 7, 8).
Moreover, it is of great importance that interactions with
commonly used anti-epileptic drugs (AEDs) are appreciated by
doctors prescribing CBD-based therapy (1, 5, 6, 11). It has
been shown that CBD may exhibit numerous interactions with
other AEDs, both enzyme inducers (such as carbamazepine or
phenytoin) and inhibitors (such as valproic acid), even if the
clinical significance not yet is clear. CBD may have an impact on
liver metabolism with significant elevation of liver enzymes in up
to 10% of treated patients, of whom more than three quarter had
received concomitant valproic acid therapy. In addition, there are
clinically significant interaction between CBD and clobazam, an
AED widely used in patients with both Dravet and LGS. The use
of CBD (by inhibition of CYP2C19) may lead to a significant
increase in clobazam metabolites, leading to toxicity. At the
same time, clobazam may increase an active metabolite of CBD,
which could lead to better seizure control. Overall, there are still
many unanswered questions regarding the impact of interactions
between CBD and other AEDs. However, due to an increased risk
of side effects such as somnolence and increased liver enzymes,
close clinical and biochemical monitoring is recommended (6,
10, 11). Moreover, it has to be emphasized that clinicians need
to report all possible severe side effects, preferably by enrolling
patients in post-authorization Phase IV safety studies.
The greatest limitation with our survey, and the one published
by Klotz et al. (7), is that that we do not have the exact
number of neuropediatricians that received the survey. We
can therefore not give an exact response rate. Certainly many
neuropediatricians on our email lists may in their daily practice
focus on other pediatric neurology subspecialties (e.g., congenital
neuromuscular disorders, cerebral palsy, and neurohabilitation)
and thus do not have the same focused interest in or experience
with therapy of refractory epilepsies. However, those who
responded were overall very experienced neuropediatricians and
around 2/3 were treating children with epilepsy on a weekly basis.
We speculate that many of those who did not respond were
less interested or familiar with the topic of CBD therapy and
refractory epilepsies.
In conclusion, this survey indicates that off-label cannabinoid-
based therapy for pediatric epilepsy in children was not widely
prescribed by neuropediatricians in Scandinavia and Germany
in 2018. However, self-medication and parental request for
this therapy was common. This may reflect a previously
reported disparity in opinion on the use of cannabinoids in
epilepsy treatment with fewer medical specialists supporting
its use compared with patients and the public (12). Evidence
from recent clinical trials and improved availability of an
approved CBD formulation will most likely change the situation
regarding CBD-based therapy for pediatric refractory epilepsy in
the future.
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